anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A randomized, double-blind, multicenter study (BOLERO-2, NCT00863655) of AFINITOR in combination with exemestane vs. placebo in combination with exemestane was conducted in 724 postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer with recurrence or progression following prior therapy with letrozole or anastrozole. Randomization was stratified by documented sensitivity to prior hormonal therapy (yes vs. no) and by the presence of visceral metastasis (yes vs. no). Sensitivity to prior hormonal therapy was defined as either (1) documented clinical benefit (complete response [CR], partial response [PR], stable disease ≥ 24 weeks) to at least one prior hormonal therapy in the advanced setting or (2) at least 24 months of adjuvant hormonal therapy prior to recurrence. Patients were permitted to have received 0-1 prior lines of chemotherapy for advanced disease. The major efficacy outcome measure was progression-free survival (PFS) evaluated by RECIST (Response Evaluation Criteria in Solid Tumors), based on investigator (local radiology) assessment. Other outcome measures included overall survival (OS) and objective response rate (ORR).

Patients were randomized 2:1 to AFINITOR 10 mg orally once daily in combination with exemestane 25 mg once daily (n = 485) or to placebo in combination with exemestane 25 mg orally once daily (n = 239). The two treatment groups were generally balanced with respect to baseline demographics and disease characteristics. Patients were not permitted to cross over to AFINITOR at the time of disease progression.

The trial demonstrated a statistically significant improvement in PFS by investigator assessment (Table 20 and Figure 1). The results of the PFS analysis based on independent central radiological assessment were consistent with the investigator assessment. PFS results were also consistent across the subgroups of age, race, presence and extent of visceral metastases, and sensitivity to prior hormonal therapy.

ORR was higher in the AFINITOR in combination with exemestane arm vs. the placebo in combination with exemestane arm (Table 20). There were 3 complete responses (0.6%) and 58 partial responses (12%) in the AFINITOR arm. There were no complete responses and 4 partial responses (1.7%) in the placebo in combination with exemestane arm.

After a median follow-up of 39.3 months, there was no statistically significant difference in OS between the AFINITOR in combination with exemestane arm and the placebo in combination with exemestane arm [HR 0.89 (95% CI: 0.73, 1.10)].

Figure 1: Kaplan-Meier Curves for Progression-Free Survival by Investigator Radiological Review in Hormone Receptor-Positive, HER-2 Negative Breast Cancer in BOLERO-2
BACKGROUND: The exact reason of nonaneurysmal subarachnoid hemorrhage (SAH) is an enigma. The aim of this study is to identify if type III deep cerebral venous drainage is exclusively prevalent in patients with nonaneurysmal SAH and to enumerate the predictors of poorer outcome in these patients.
METHODS: All patients of age >18 years, presented at our centre with spontaneous SAH on noncontrast computed tomography head and were divided into 2 groups, aneurysmal and nonaneurysmal SAH after 4-vessel DSA. Based on the deep venous drainage pattern on both sides, basal venous drainage was found and classified into 3 types: type I, type II, and type III. The 3 groups were pitted against one another. Regression analysis were performed to predict the occurrence of nonaneurysmal-SAH with different types of basal vein.
RESULTS: There were 100 nonaneurysmal SAH cases and 103 aneurysmal SAH cases. The mean age of presentation was 47.8 ± 13.55 years with slight male predominance (52%). The patients with type III venous drainage have 2 times more risk of developing nonaneurysmal SAH (95% confidence interval = 1.21-4.31) as compared to those with aneurysmal SAH. On multivariate analysis, type III basal venous drainage, worse Hunt and Hess grade at presentation, extensive bleeding were predictors of an adverse outcome.
CONCLUSIONS: The presence of type III venous distribution is associated with a 2-fold increase in the probability of having nonaneurysmal SAH, as well as a 3-fold increase in the risk of developing poorer neurological sequelae.
The present disclosure belongs to the field of health care products, disclosing a powder made from synanthrin, Longan Arillus, Jujubae Fructus, Lycii Fructus, Rehmanniae Radix Praparata, Juglandis Semen, Cistanche tubulosa (Schenk) Wight, taurine, Schisandrae Chinensis Fructus and Cinnamomi Cortex. The raw materials of the powder are all from natural Chinese herbal medicine without addition of excipient. It is clean and has natural components, in line with people's pursuit of natural and health foods. In addition, dosage required for the powder is small; it can be taken orally or dissolved in water; it is soluble in cold water and melts in mouth; it has a good taste and can be absorbed quickly. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. The powder obtained has a good stability and long storage time. Experiments show that the powder of the present disclosure can promote the growth of experimental animals, enhance the sperm activity of the animals, improve the sex reaction time and frequency, and increase the level of sex hormones and sexual organ coefficient. The powder can significantly improve sexual capacity, therefore can be used to prepare the health care foods having function on improving sexual capacity.
Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION.
PROBLEM TO BE SOLVED: To produce crystallographically high purity fluorapatite contg. no unreacted substance or by-product with a comparatively simple process by maintaining an aqueous suspension of powdery CaHPO4 .2H2 O, fine powder CaCO3 and fine powder CaF2 fine particles at a specified temp. or higher. SOLUTION: The objective fluorapatite(FAP) is produced by heating an aqueous suspension of powdery CaHPO4 .2H2 O, fine powder CaCO3 having a <=5μm average particle size and powdery CaF2 having a <=10μm average particle size to >=70 deg.C and maintaining the suspension at this temp. to allow it to react. In this production, when the average particle size of the powdery CaCo3 is >5μm, the reaction proceeds insufficiently under the reaction conditions (at >=70 deg.C) and remaining of powdery CaF2 in the reaction product or formation of F-CO3 apatite is caused and therefore, high purity FAP cannot be produced.  Also, powdery CaF2 is provided with almost equivalent reactivity to that of the powdery CaCO3 by employing the fine powder CaF2 having a <=10μm average particle size and the reaction of this powdery CaF2 with the powdery CaHPO4 .2H2 O is able to completely proceed concurrently with the reaction of the powdery CaCO3 with the powdery CaHPO4 .2H2 O.
1,133,881. Hair lacquers. L'OREAL. 6 Sept., 1966 [6 Sept., 1965], No. 39845/66. Heading A5B [Also in Divisions C3 and C4] A hair lacquer or hair setting lotion comprises an alcoholic or aq. alcoholic solution of a coloured resin consisting of recurring units of formula where D is the residue of a dye having a hydroxyl or a primary or secondary amino group, A is the residue of an alcohol and B is the residue of an ethylenically unsaturated monomer, the resin being the condensation product at least one of the above dyes and at least one alcohol with a maleic anhydride/ ethylenically unsaturated monomer copolymer obtained from 45-55 mole % maleic anhydride and 55-45 mole % of the unsaturated monomer. In examples the coloured resin was compounded with a vinyl acetate/crotonic acid copolymer, 2-amino-2-methyl-propanol, ethyl alcohol, water and optionally an aerosol propellant.
A method of monitoring compliance of a patient that has been placed on a medication maintenance program with a prescribed medication dosage by determining a normalized urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration and urine specific gravity are measured. The normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine and the urine specific gravity. The calculated normalized urine medication concentration is compared with an expected medication concentration value for the patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance. Alternatively, a urinary-parameter normalized urine medication concentration is calculated as a function of the measured medication concentration in the urine, the urine specific gravity and at least one selected pharmacokinetic parameter of the medication. The calculated urinary-parameter normalized urine medication concentration is compared with an expected medication concentration value for an average compliant patient for the maintenance program prescribed to determine any significant differences therebetween as an indication of noncompliance.
The invention relates to a medicine cefotiam hydrochloride composition for treating the bacterial infection, and belongs to the technical field of medicines. The composition is composed of cefotiam hydrochloride and sodium dihydrogen phosphate. The cefotiam hydrochloride is a crystal. An X-ray powder diffraction pattern obtained through measurement by means of Cu-K alpha ray is shown in a figure 1. The novel crystal form of the hydroxyfasudil is different from a crystal form structure in the prior art. According to experimental verification, surprisingly, it is found that the novel crystal-form compound is high in purity, good in mobility and stability, low in polymer content and not prone to moisture absorption, the obtained powder injection is matched with a 0.9% sodium chloride injection, 5% glucose injection and 5% sodium chloride and dextrose injection and the stability of the solution is good after the solution is placed at the room temperature for 4 h.
PURPOSE:To obtain an aerosol composition capable of being left as it is because natural decomposition after application to damaged skin, comprising a biodegradable hydroxycarboxylic acid polymer such as lactic acid polymer or glycolic acid polymer as a film-forming component. CONSTITUTION:In an aerosol composition comprising a film-forming component, a solvent, a propellant and optionally an active ingredient of medicine, a repellent against insect pests, a surfactant, etc., a biodegradable hydroxycarboxylic acid polymer is used as the film-forming component. A monopolymer or a copolymer wherein a hydroxycarboxylic acid of the formula (R is H or 1-8C alkyl) is subjected to polyester bond is preferable as the biodegradable hydroxycarboxylic acid. A lactic acid polymer or a lactic acid-glycolic acid copolymer having 1,000-400,000 molecular weight is most preferable. The amount of the polymer is about 0.01-20wt.% based on the whole composition. Dimethyl ether is preferable as the propellant. This composition neither provides a feeling of pain nor falls and an ache will not occur even in coming into contact with water.
The invention discloses a recombinant canine influenza virus strain and a preparation method thereof as well as a vaccine prepared from the recombinant canine influenza virus strain. A recombinant canine influenza virus comprises HA and NA genes of a H3N2 subtype canine influenza virus and six internal genes of a H9N2 avian influenza virus including PB2, PB1, PA, NP, M and NS. The recombinant canine influenza virus strain disclosed by the invention is named after rH3N2-DL. The preservation number of the recombinant canine influenza virus strain disclosed by the invention is CGMCC No.8162. The invention further discloses the preparation method of the recombinant canine influenza virus and the vaccine prepared from the recombinant canine influenza virus. Compared with the parental strain, the recombinant canine influenza virus disclosed by the invention has high virus titer and blood congeal titer both on chick embryos and MDCK cells. Animal experimental results show that the vaccine prepared from the recombinant canine influenza virus has good immunogenicity and protective efficacy.
The invention generally provides compositions and methods for promoting and enhancing wound closure and healing. Specifically, the invention provides a biologic composition which comprises a support layer which serves as transport scaffold, for example made of gelatin, which is coated or impregnated with a bio-adhesive molecule such as rose bengal or glyceraldehyde. The composition can also comprise an artificial or biological matrix, optionally processed (i.e. cleaned and coated with extracellular matrix proteins) to enhance cell attachment and survival. The composition can further comprise a monolayer of epithelial, endothelial cells or mesenchymal cells. The invention provides methods for using the compositions for treating wounds due to disease, trauma or surgery. Specific methods for treating ocular wounds are provided.
A composition having one or more targeted opioids for administration by inhalation is provided. Targeted opioids include morphine, morphine sulfate, 6 mono acetyl morphine, morphine-6-glucuronide, morphine-6-glucuronide bromide, morphine-6-glucuronide acetate, morphine-6-glucuronide sulfate or other salt forms of these aforementioned substances. One or more targeted opioids is combined with an excipient to formulate a composition useful in the treatment of pain, anxiety or other indications. Herein, these mixtures will be referred to as "opioid compositions." Compositions are administered in a gaseous state through the use of a novel heat-activated drug inhalation device. Kits and methods of administration of the targeted opioid composition are also provided. The composition and kit are designed for the safe delivery of opioids whereby overdose and death is extremely unlikely because of the properties of the new drug and new delivery system.
The effectiveness of Risperidone for Extended-Release Injectable Suspension in the treatment of schizophrenia was established, in part, on the basis of extrapolation from the established effectiveness of the oral formulation of risperidone. In addition, the effectiveness of Risperidone for Extended-Release Injectable Suspension in the treatment of schizophrenia was established in a 12-week, placebo-controlled trial in adult psychotic inpatients and outpatients who met the DSM-IV criteria for schizophrenia.

Efficacy data were obtained from 400 patients with schizophrenia who were randomized to receive injections of 25 mg, 50 mg, or 75 mg Risperidone for Extended-Release Injectable Suspension or placebo every 2 weeks. During a 1-week run-in period, patients were discontinued from other antipsychotics and were titrated to a dose of 4 mg oral risperidone. Patients who received Risperidone for Extended-Release Injectable Suspension were given doses of oral risperidone (2 mg for patients in the 25 mg group, 4 mg for patients in the 50 mg group, and 6 mg for patients in the 75 mg group) for the 3 weeks after the first injection to provide therapeutic plasma concentrations until the main release phase of risperidone from the injection site had begun. Patients who received placebo injections were given placebo tablets.

Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS), a validated, multi-item inventory, composed of five subscales to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression.

The primary efficacy variable in this trial was change from baseline to endpoint in the total PANSS score. The mean total PANSS score at baseline for schizophrenic patients in this study was 81.5.

Total PANSS scores showed significant improvement in the change from baseline to endpoint in schizophrenic patients treated with each dose of Risperidone for Extended-Release Injectable Suspension (25 mg, 50 mg, or 75 mg) compared with patients treated with placebo. While there were no statistically significant differences between the treatment effects for the three dose groups, the effect size for the 75 mg dose group was actually numerically less than that observed for the 50 mg dose group.

Subgroup analyses did not indicate any differences in treatment outcome as a function of age, race, or gender.
1475861 Treatment of depression WARNER LAMBERT CO 19 March 1976 [21 March 1975] 11887/75 Heading A5B Anhydrous pharmaceutical compositions for use in the treatment of depression comprise a non-toxic, water-soluble salt of tryptophan e.g. its sodium or potassium salt or its hydrochloride, an effervescent couple and an anhydrous, water-soluble flavouring e.g. a lemon or peppermint flavouring. The effervescent couple may comprise at least one alkali metal carbonate and/or bicarbonate e.g. sodium bicarbonate, and at least one solid non-toxic organic acid e.g. citric, tartaric, malic, fumaric or adipic acid. The compositions may also contain at least one permitted food colouring and/or at least one natural and/or synthetic sweetening agent. The compositions may be in the form of a powder or granulate preferably packed into sachets, each of which contains a single dose, or in the form of tablets which may be individually packed which when dissolved in water gives a clear, sparkling and orally palatable solution.
Prematurity with mild retinopathy of prematurity. ROP not needing treatment. Prematurity was defined as birth at \< 37 weeks gestation.
Identifying macular neovascularization (MNV) in eyes with central serous chorioretinopathy (CSC) has important implications for its management. Optical coherence tomography angiography (OCTA) is increasingly used for this purpose. Here, we systematically reviewed the literature and conducted meta-analysis to determine the diagnostic accuracy of OCTA for detecting MNV in eyes with CSC. We systematically searched the literature in 12 databases for relevant studies from database inception until 18 November 2023. Eligible studies had eyes with CSC with MNV and CSC without MNV. Index test was OCTA. Reference test was retinal dye angiography. Study selection and data extraction were performed in duplicate, and study was evaluated using the Quality Assessment of Diagnostic Accuracy Studies 2. Our main outcome of interest was the sensitivity and specificity of OCTA for detecting MNV in CSC. Pooled diagnostic test accuracy estimates were computed using MetaDTA. Of 177 records screened, seven fulfilled the eligibility criteria for our study. These studies summarized data from a total of 1061 eyes. Summary estimate sensitivity and specificity to diagnose MNV in eyes with CSC using OCTA was 92.9% (95% CI: 81.7%-97.5%) and 99.4% (95% CI: 84.1%-100.0%), respectively. The main source of bias across studies was the reference standard, as four studies used multimodal imaging including OCTA for the reference standard. OCTA alone is excellent for detecting MNV in CSC compared to retinal dye angiography or multimodal imaging. Using OCTA first before considering retinal dye angiography could potentially save an important number of retinal dye angiographies.
Type 2 diabetes mellitus is a major health concern in the United States, accounting for 90 to 95% of the more than 25 million diagnosed cases of diabetes in 2010. Racial and ethnic minorities are disproportionately affected by the diabetes epidemic, specifically African Americans, Latinos, and Native Americans. Although the cumulative evidence suggests that lifestyle interventions to prevent diabetes can be implemented across a variety of settings with diverse personnel, numerous barriers to widespread dissemination in minority populations still exist. Latinos Combatiendo la Diabetes (La Comunidad) is a 225-participant randomized trial designed to test the hypothesis that a community-based lifestyle weight-loss intervention implemented within the accountability and structure of existing Latino communities will have a more beneficial and clinically meaningful impact on HbA1c, insulin metabolism, and markers of the metabolic syndrome when compared to an enhanced usual care condition. An economic evaluation will also be conducted to determine costs and cost-effectiveness. One trial arm will consist of a group-based intensive lifestyle intervention promoting healthy eating, increased physical activity and modest, yet achievable (5-7%) weight loss delivered in an early 6-month intensive phase followed by an 18-month maintenance phase. Latino Health Advisors (LHAs) will be utilized in the intensive intervention arm. The control arm will consist of an individual educational intervention that incorporates existing community resources that are available to assist residents in making healthier lifestyle choices.
In Finland, the frequency of isolated cleft palate (CP) is higher than that of isolated cleft lip with or without cleft palate (CL/P). This trend contrasts to that in other European countries but its genetic underpinnings are unknown. We conducted a genome-wide association study in the Finnish population and identified rs570516915, a single nucleotide polymorphism highly enriched in Finns, as strongly associated with CP (P = 5.25 × 10-34, OR = 8.65, 95% CI 6.11-12.25), but not with CL/P (P = 7.2 × 10-5), with genome-wide significance. The risk allele frequency of rs570516915 parallels the regional variation of CP prevalence in Finland, and the association was replicated in independent cohorts of CP cases from Finland (P = 8.82 × 10-28) and Estonia (P = 1.25 × 10-5). The risk allele of rs570516915 alters a conserved binding site for the transcription factor IRF6 within an enhancer (MCS-9.7) upstream of the IRF6 gene and diminishes the enhancer activity. Oral epithelial cells derived from CRISPR-Cas9 edited induced pluripotent stem cells demonstrate that the CP-associated allele of rs570516915 concomitantly decreases the binding of IRF6 and the expression level of IRF6, suggesting impaired IRF6 autoregulation as a molecular mechanism underlying the risk for CP.
[Problem] To provide an anti-human TWEAK antibody having superior activity as compared to conventional anti-human TWEAK antibodies, and a means for preventing or treating various diseases in which human TWEAK is involved in the pathogenesis using this antibody. [Solution] Anti-human TWEAK antibody containing each of: a heavy-chain variable region comprising an amino acid sequence of amino acids nos. 1 to 118 of SEQ ID NO: 1, an amino acid sequence of amino acids nos. 1 to 125 of SEQ ID NO: 5, or an amino acid sequence of amino acids nos. 1 to 121 of SEQ ID NO: 9; and a light-chain variable region comprising an amino acid sequence of amino acids nos. 1 to 108 of SEQ ID NO: 3, an amino acid sequence of amino acids nos. 1 to 108 of SEQ ID NO: 7, or an amino acid sequence of amino acids nos. 1 to 108 of SEQ ID NO: 11.